• Does the United States Need Better Policies Governing Generic Drug Use?

    Mar 1, 2023, 00:00

  • Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone

    Mar 1, 2023, 00:00

  • The “Affordable Medicines” Reimbursement Program in Ukraine: Framework Assessment and Impact Evaluation

    Mar 1, 2023, 00:00

  • The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom

    Mar 1, 2023, 00:00

  • Editorial Board

    Feb 7, 2023, 10:35

  • Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years

    Feb 1, 2023, 00:00

  • Preferences for Sexually Transmitted Infection and Cancer Vaccines in the United States and in China

    Feb 1, 2023, 00:00

  • The Impact of Sharing Drug Rebates at the Point of Sale on Out-of-Pocket Payments for Enrollees in Employer-Sponsored Insurance

    Feb 1, 2023, 00:00

  • Table of Contents

    Feb 1, 2023, 00:00

  • Disease-Related Loss to Government Funding: Longitudinal Analysis of Individual-Level Health and Tax Data for an Entire Country

    Feb 1, 2023, 00:00

  • Can Observational Analyses of Routinely Collected Data Emulate Randomized Trials? Design and Feasibility of the Observational Patient Evidence for Regulatory Approval Science and Understanding Disease Project

    Feb 1, 2023, 00:00

  • Modifying the Composite Time Trade-Off Method to Improve Its Discriminatory Power

    Feb 1, 2023, 00:00

  • A Roadmap for Increasing the Usefulness and Impact of Patient-Preference Studies in Decision Making in Health: A Good Practices Report of an ISPOR Task Force [Editor's Choice]

    Feb 1, 2023, 00:00

  • Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib [Editor's Choice]

    Feb 1, 2023, 00:00

  • Quality-Adjusted Life Expectancy Norms for the English Population [Editor's Choice]

    Feb 1, 2023, 00:00

  • Navigating Patient-Preference Studies for Cross-Stakeholder Decision Making: A Roadmap Guides the Way

    Feb 1, 2023, 00:00

  • Generic Health-Related Quality of Life Utility Measure for Preschool Children (Health Utilities Preschool): Design, Development, and Properties

    Feb 1, 2023, 00:00

  • A Scoping Review of the Use of Machine Learning in Health Economics and Outcomes Research: Part 1—Data From Wearable Devices [Editor's Choice]

    Feb 1, 2023, 00:00

  • The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis

    Feb 1, 2023, 00:00

  • The Prader-Willi Syndrome Anxiousness and Distress Behaviors Questionnaire: Development and Psychometric Validation

    Feb 1, 2023, 00:00

  • Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework? [Editor's Choice]

    Feb 1, 2023, 00:00

  • A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies

    Feb 1, 2023, 00:00

  • Copyright/Subscription

    Feb 1, 2023, 00:00

  • Gradient Boosted Tree Approaches for Mapping European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Onto 5-Level Version of EQ-5D Index for Patients With Cancer

    Feb 1, 2023, 00:00

  • Comprehensive Score for Financial Toxicity and Health-Related Quality of Life in Patients With Cancer and Survivors: A Systematic Review and Meta-Analysis

    Feb 1, 2023, 00:00

  • Editorial Board

    Jan 9, 2023, 08:36

  • Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges [Editor's Choice]

    Jan 1, 2023, 00:00

  • Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic Review [Editor's Choice]

    Jan 1, 2023, 00:00

  • Patient-Reported Satisfaction, Experiences, and Preferences: Same but Different? [Editor's Choice]

    Jan 1, 2023, 00:00

  • For Me or for My Relatives? Approximating Self-Protection and Local Altruistic Motivations Underlying Preferences for Public Health Policies Using Risk Perception Metrics

    Jan 1, 2023, 00:00

  • Assessment of the Social Security Administration Death Master File for Comparative Analysis Studies of Peripheral Vascular Devices

    Jan 1, 2023, 00:00

  • Heterogeneous Preferences for Colorectal Cancer Screening in Germany: Results of a Discrete Choice Experiment

    Jan 1, 2023, 00:00

  • Patient and Caregiver Experience Decision Factors in Treatment Decision Making: Results of a Systematic Literature Review of Multiple Myeloma Decision Aids

    Jan 1, 2023, 00:00

  • Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer

    Jan 1, 2023, 00:00

  • A Data-Driven Approach to Support the Understanding and Improvement of Patients’ Journeys: A Case Study Using Electronic Health Records of an Emergency Department

    Jan 1, 2023, 00:00

  • Patient Expectations About Palliative Treatment for Symptomatic Spinal Metastases: A Qualitative Study

    Jan 1, 2023, 00:00

  • Table of Contents

    Jan 1, 2023, 00:00

  • Enhancing Patient Centricity of Real-World Data Research: An Exploratory Analysis Using the Patient Experience Mapping Toolbox

    Jan 1, 2023, 00:00

  • Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations From a Consensus Process

    Jan 1, 2023, 00:00

  • Test-Retest Reliability of EQ-5D-Y-3L Best-Worst Scaling Choices of Adolescents and Adults

    Jan 1, 2023, 00:00

  • Valuing Health Gain from Composite Response Endpoints for Multisystem Diseases

    Jan 1, 2023, 00:00

  • Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer

    Jan 1, 2023, 00:00

  • Copyright/Subscription

    Jan 1, 2023, 00:00

  • Cost-Effectiveness of a Specialized Breathlessness Service Versus Usual Care for Patients With Advanced Diseases

    Jan 1, 2023, 00:00

  • Measuring, Analyzing, and Presenting Work Productivity Loss in Randomized Controlled Trials: A Scoping Review

    Jan 1, 2023, 00:00

  • The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data [Editor's Choice]

    Jan 1, 2023, 00:00

  • CO117 Assessing the Impact of Hospital Characteristics on Outcomes of Outpatient Cardiac Procedures: An Analysis of the HCUP-NASS 2019 Database

    Dec 14, 2022, 09:50

  • CO175 Systematic Literature Review of Outcomes in Patients With Advanced Basal Cell Carcinoma (ABCC) Who Progressed on or Are Intolerant to Hedgehog Inhibitors (HHI)

    Dec 1, 2022, 00:00

  • PCR210 Quality of Life and Productivity Losses of Dysmenorrhea Patients in Korea

    Dec 1, 2022, 00:00

  • EE142 The Clinical Benefits and Costs of Potential Cervical Cancer Screening Strategies in the Czech Republic

    Dec 1, 2022, 00:00

  • HTA154 Comparing Non-Oncological Rare Condition Submissions to the National Institute for Health and Care Excellence (NICE) Versus Scottish Medicines Consortium (SMC) From 2001 to 2021

    Dec 1, 2022, 00:00

  • HTA124 Real-World Data to Inform Health Technology Assessments in England: A Review of Submissions to the National Institute for Health and Care Excellence Since 2018

    Dec 1, 2022, 00:00

  • EE248 Cost Effectiveness of Novel Antiobiotic Imipenem/Cilastatin/Relebactam in Gram Negative Infections in Greece

    Dec 1, 2022, 00:00

  • PCR136 Patient and Health Care Professional Experiences of Suboptimal Insulin Dosing

    Dec 1, 2022, 00:00

  • P19 How Is Real-World Evidence Really Being Used in Health Technology Assessments – A Canadian Case Study

    Dec 1, 2022, 00:00

  • EE580 Costs of Chronic Kidney Failure and Diabetic Nephropathy in Turkiye

    Dec 1, 2022, 00:00

  • PCR32 Self-Reported Prevalence and Impact of Clinical Signs, Symptoms, and Events in Adults With Osteogenesis Imperfecta (OI)

    Dec 1, 2022, 00:00

  • HPR44 Innovation Value Framework - Evidence From EU-4 and UK

    Dec 1, 2022, 00:00

  • MSR54 A Comparison of MAIC and STC Methods to Support the Decision at Feasibility Assessment Stage

    Dec 1, 2022, 00:00

  • EE621 Cost of Illness of Vaccine-Preventable Diseases in France

    Dec 1, 2022, 00:00

  • EPH182 Inpatient Burden of Respiratory Syncytial Virus in Children ≤2 Years of Age in Germany: A Retrospective Analysis of Nationwide Hospitalization Data, 2019-2021

    Dec 1, 2022, 00:00

  • EE562 Cost-Effectiveness and Budget Impact Analyses of Implementing the First Pillar of Patient Blood Management, With Intravenous (IV) Ferric Carboxymaltose (FCM), on the Turkish Healthcare System

    Dec 1, 2022, 00:00

  • CO146 Potential Predictors Affecting Access to Breast Cancer Screening Among Women in the United States Using the Health Behavioral Model: A MEPS Panel Analysis

    Dec 1, 2022, 00:00

  • EE335 Cost-Efectiveness Analysis Between Multichambered Standarized Pediatric Parental Nutrition and Individualized Compounded Parental Nutrition, Analysis From the Mexican Public Health System Perspective

    Dec 1, 2022, 00:00

  • MT31 A Novel Medical Technology for Rapid Molecular Diagnostics (Nicking Enzyme Amplification Reaction [NEAR]) - A Systematic Literature Review, Meta-Analysis

    Dec 1, 2022, 00:00

  • PCR63 Using Patient Preference to Inform Ritlecitinib Dose Selection for Alopecia Areata Treatment

    Dec 1, 2022, 00:00

  • HPR159 Neovascular Age-Related Macular Degeneration (NAMD) in Italy: A Social Cost Analysis

    Dec 1, 2022, 00:00

  • HTA99 NICE Evaluations of Oncology Products With EMA Conditional Marketing Authorisation

    Dec 1, 2022, 00:00

  • HSD68 Barriers and Facilitators of Shared Decision Making in Clinical Practi An Umbrella Review

    Dec 1, 2022, 00:00

  • EE656 A Cost-Utility Analysis of Avacopan for the Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, a Rare Disease, in Spain

    Dec 1, 2022, 00:00

  • EE121 Cost-Effectiveness of Family Based Treatment for Pediatric Obesity: A Literature Review

    Dec 1, 2022, 00:00

  • HPR19 Tax Revenue Gains and Societal Net-Monetary Benefit Associated With Implementing Lung Cancer Screening in the United Kingdom

    Dec 1, 2022, 00:00

  • HTA175 Health Technology Assessment Decisions in Sweden and Denmark: A Comparative Study in Understanding the Challenges of Approval for Single-Arm Trials

    Dec 1, 2022, 00:00

  • HTA7 Implementation of Comprehensive Criteria for Decision Making Process of Pricing and Reimbursement in Algeria

    Dec 1, 2022, 00:00

  • PCR83 Investigation of Functional Outcomes at Hospital Discharge in Hip Replacement Patients in Different Health Care Sectors

    Dec 1, 2022, 00:00

  • P26 Disinvestment Impact, Processes, Policies and Experiences Worldwide: A Systematic Review

    Dec 1, 2022, 00:00

  • EPH29 The Cost of Managing Safety Events: Ozanimod Versus Tofacitinib – A UK Perspective

    Dec 1, 2022, 00:00

  • PCR231 Associations of Preoperative Anxiety/Depression (EQ-5D-5L) With Pre- and Postoperative Health-Related Quality of Life for Hip and Knee Replacement

    Dec 1, 2022, 00:00

  • RWD8 Patient Preferences in Chronic Immune-Mediated Inflammatory Diseases Potentially Treated With Biological Drugs: Real-World Data Analysis

    Dec 1, 2022, 00:00

  • HTA16 Purchasing Implantable Medical Devices in Egypt Using a Multicriteria Decision Analysis (MCDA) Tool

    Dec 1, 2022, 00:00

  • EE457 Forecasting Social Welfare GainsFfrom Biosimilar Entries in the Basal Insulin Market

    Dec 1, 2022, 00:00

  • EE28 Cost-Effectiveness of Glucose-Lowering Therapies as Add-on to Standard Care for People With Type 2 Diabetes in Malaysia

    Dec 1, 2022, 00:00

  • HTA102 Machine-Learning Technology Assisted Curated Reference Libraries as an Approach for Rapid Global Value Dossier Updates to Support Living Health Technology Assessment: A Case Study in Triple Refractory Multiple Myeloma (TRMM)

    Dec 1, 2022, 00:00

  • EE133 Budget Impact Related to Complications on Post-Bariatric Surgery Patients in Brazilian Public Healthcare System

    Dec 1, 2022, 00:00

  • EE376 Cost-Effectiveness of Complete Guideline-Adherent Use of Coronary Angiography From the German Payer Perspective

    Dec 1, 2022, 00:00

  • MSR88 Can the Promis®-29 Profile be Used to Predict SF-36 Physical and Mental Health Summary Scores?

    Dec 1, 2022, 00:00

  • EE385 Cost Effectiveness of Gender-Neutral Vaccination With Gardasil 9 Against HPV in Greece

    Dec 1, 2022, 00:00

  • CO81 A Bayesian Approach to Increase Evidence of Effectiveness in Health Economic Evaluations of Treatments for Rare Diseases

    Dec 1, 2022, 00:00

  • HTA218 Best Practices for ECA Study Design to Support HTA Decision-Making in Europe

    Dec 1, 2022, 00:00

  • EE448 Assessing the Cost-Effectiveness of Reducing Acute Exacerbations in Patients With COPD

    Dec 1, 2022, 00:00

  • EPH126 Sex- and Age-Adjusted Incidence and Prevalence Population-Based Estimation for Acute Myeloid Leukemia in Korea From 2011 to 2019

    Dec 1, 2022, 00:00

  • PCR31 Patient and Caregiver Preferences for the Treatment of Duchenne Muscular Dystrophy: A Quantitative Patient Preference Study

    Dec 1, 2022, 00:00

  • EE541 Cost-Effectiveness and Epidemiological Impact of a Novel 3-Antigen Vaccine for the Prevention of Hepatitis B in Adults in the United Kingdom

    Dec 1, 2022, 00:00

  • MSR100 Applicability of Artificial Intelligence in Targeted Literature Review

    Dec 1, 2022, 00:00

  • HTA232 Indirect Treatment Comparison Methods in NICE Immuno-Oncology Technology Appraisals: Implementation and Critique

    Dec 1, 2022, 00:00

  • MSR31 Evidence Synthesis for Decision-Making: Is Meta-Analysis Always Required?

    Dec 1, 2022, 00:00

  • HTA100 Association of NCPE Submission Outcomes in Ireland With Added Therapeutic Value (ASMR) Rating in France

    Dec 1, 2022, 00:00

  • HPR43 Differences in Inequalities of Uterine Cancer Treatment Before and After COVID-19 in England

    Dec 1, 2022, 00:00

  • EPH96 Risk Factors for Below-the-Knee Amputation in Japanese Patients With Critical Limb Ischemia Who Underwent Plain Old Balloon Angioplasty Therapy: A Claims Database Analysis

    Dec 1, 2022, 00:00

  • PCR237 Effect of Eptinezumab on Utility Scores in Patients With Migraine: Results From the Deliver Study

    Dec 1, 2022, 00:00

  • HSD115 Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec

    Dec 1, 2022, 00:00

  • EPH45 Socio-Demographic Determinants of Childhood Vaccination in Indonesia: A Cross-Sectional Study

    Dec 1, 2022, 00:00

  • HSD2 Reusable Soft Mist Inhalers Have an Improved Carbon Footprint Compared With Dry Powder Inhalers and Pressurised Metered-Dose Inhalers

    Dec 1, 2022, 00:00

  • CO30 Therapeutic Role of Melatonin in Pediatric Migraine: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • HPR207 Are the Incremental Added Benefit and Price Claimed in Agreement With the Clinical Evaluation and the Price Setting? A Retrospective Analysis in France (2016-2021)

    Dec 1, 2022, 00:00

  • HPR154 Appropriate Use of Anti-PD(L)1 in Paris Public Hospitals (AP-HP): Are the Prescriptions in Compliance with Reimbursed Indications?

    Dec 1, 2022, 00:00

  • EPH52 Odds Ratio of Each Disease Before Incidence of Alzheimer's Disease - A Case Control Study Using Japanese Health Insurance Claims Data

    Dec 1, 2022, 00:00

  • CO4 How Can the Long-Term Benefits and Harms of Screening Be Transparently Quantified and Contrasted for Informed Decision-Making? Colorectal Cancer Screening for Persons at Familial Risk (FARKOR)

    Dec 1, 2022, 00:00

  • EE311 Polyethylene Glycol Hydrogel Versus Fibrin Glue Sealant for Posterior Fossa Surgery: A Budget-Impact Analysis in Five European Countries

    Dec 1, 2022, 00:00

  • EE291 Economic Evaluation of Metastatic Breast Cancer Following Trastuzumab-Based Treatment of HER2+ Early Breast Cancer in Hong Kong

    Dec 1, 2022, 00:00

  • EE79 Cost-Effectiveness of Earlier Whole-Genome Sequencing in Rare Genetic Childhood Epilepsy

    Dec 1, 2022, 00:00

  • EE102 Economic and Organisational Impact of an Innovative Treatment With Extended Durability for Retinal Diseases Reducing the Annual Frequency of Intravitreal Injections in France

    Dec 1, 2022, 00:00

  • HPR172 How Thalassemia Is Prevented in China: A Policy Review and International Comparison

    Dec 1, 2022, 00:00

  • HPR208 Analysis of Substitution Procurement Agreements and Financial Impact in a University Hospital Structure

    Dec 1, 2022, 00:00

  • HPR1 Development of an Economic Evaluation Guideline in Lebanon

    Dec 1, 2022, 00:00

  • EE630 A Cost-Effectiveness Analysis (CEA) of Adjuvant Nivolumab for Patients With Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in France

    Dec 1, 2022, 00:00

  • PCR154 Modelling Time-to-Death Utilities as a Continuous Function, Using a Rich Dataset of Patients With Non-Small Cell Lung Cancer

    Dec 1, 2022, 00:00

  • EE661 Impact on Health-Economic Evaluations of the Extrapolation Method Regarding the Efficacy of Immunotherapies: Case Study in Renal Cell Carcinoma

    Dec 1, 2022, 00:00

  • CO68 Pooled Subgroup Analysis of Patient-Reported Outcomes at Week 52 Among Patients Achieving the Primary Endpoint of F-VASI75 at Week 24 in Two Randomized Phase 3 Studies of Ruxolitinib Cream for the Treatment of Vitiligo

    Dec 1, 2022, 00:00

  • EE408 Economic Evaluation of Endovascular Therapy for Acute Stroke With a Large Ischemic Region in China

    Dec 1, 2022, 00:00

  • MT15 Obvio-19 App Ease of Use of Cancer Patients for Reporting COVID-19 Symptomology (ONCOVID Study)

    Dec 1, 2022, 00:00

  • EE251 A Budget Impact Analysis of the Introduction of Generics Ambrisentan and Tadalafil for the Treatment of Pulmonary Arterial Hypertension in Greece

    Dec 1, 2022, 00:00

  • EE518 An Early Cost-Effectiveness Analysis of Minimally Invasive Paddle-Type Spinal Cord Stimulation for the Treatment of Chronic Neuropathic Pain

    Dec 1, 2022, 00:00

  • EE674 Economic Burden of Patients With Glioblastoma in Five Key European Countries: A Systematic Review

    Dec 1, 2022, 00:00

  • EPH70 Transcription Errors in Ophthalmology: Current Burden and the Opportunity for Digital Technologies

    Dec 1, 2022, 00:00

  • HTA201 Access Challenges of Advanced Therapy Medicinal Products in Europe

    Dec 1, 2022, 00:00

  • HTA246 The SMC Ultra-Orphan Framework: 3-Year Report Card

    Dec 1, 2022, 00:00

  • EE567 Environmental Impact and Sustainability of Surgical Sets: The 4S Approach

    Dec 1, 2022, 00:00

  • RWD112 Can ML-Extracted Variables Reproduce Real World Comparative Effectiveness Results From Expert-Abstracted Data? A Case Study in Metastatic Non-Small Cell Lung Cancer Treatment

    Dec 1, 2022, 00:00

  • PCR240 A Cross-Sectional Study of Disease Severity and Health Related Quality of Life in Epidermolysis Bullosa

    Dec 1, 2022, 00:00

  • MT24 Oxidized Zirconium Can Positively Impact Outcomes in Revision Arthroplasty: A 90-Day Episode of Care Analysis in a Large US Metropolitan Statistical Area (MSA) Following Revision Knee (RKA) and Hip Arthroplasty (RHA)

    Dec 1, 2022, 00:00

  • HPR183 Could Netflix Based Subscription Models Tackle the Shrinking Antibiotic Pipeline?

    Dec 1, 2022, 00:00

  • HPR149 Global Pricing, Reimbursement and Market Access Trends for Regenerative Medicines, ATMPs, Cell, Gene Therapies

    Dec 1, 2022, 00:00

  • RWD86 Healthcare Resource Utilization (HCRU) of United States ROS1+ Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Tyrosine Kinase Inhibitors (TKIs): Analysis of Electronic Medical Transcription Records

    Dec 1, 2022, 00:00

  • HTA244 Inclusion of Carer Health-Related Quality of Life (HRQOL) in National Institute for Health and Care Excellence (NICE) Appraisals Published Since 2019

    Dec 1, 2022, 00:00

  • HTA187 Best Practices for the Development of Budget Impact Models at Regional Level

    Dec 1, 2022, 00:00

  • HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe

    Dec 1, 2022, 00:00

  • PCR95 Functional Quality of Life Among People Living With Obesity: A Longitudinal Cohort of Patient Reported Outcomes

    Dec 1, 2022, 00:00

  • MSR67 Automation of Abstract Screening: A Case Study of Multiple Systematic Literature Reviews

    Dec 1, 2022, 00:00

  • MSR92 Challenges to Implementing Real-World Evidence (RWE)

    Dec 1, 2022, 00:00

  • HTA5 Methodological Frameworks for the HTA of Digital Health Technologies: A National and International Survey

    Dec 1, 2022, 00:00

  • HPR68 Retrospective Analysis of the Negotiation in AIFA for New Therapeutic Indications

    Dec 1, 2022, 00:00

  • PCR264 Quality of Life and Disability Among Patients With Chronic Lower Back Pain

    Dec 1, 2022, 00:00

  • EPH103 Vitiligo in Italy Through Administrative Healthcare Data

    Dec 1, 2022, 00:00

  • PCR17 Capturing the Impact of Grief and Bereavement on Caregivers in NICE HST Appraisals

    Dec 1, 2022, 00:00

  • CO48 Systematic Literature Review and Meta-Analysis of Endoscopic Improvement for Treatment of Moderate-Severe Ulcerative Colitis

    Dec 1, 2022, 00:00

  • EE319 Building a Cost-Effectiveness Model for Hypertrophic Cardiomyopathy: A Literature Review

    Dec 1, 2022, 00:00

  • EE640 Quantifying Out-of-Pocket Expenses in Patients With Prurigo Nodularis

    Dec 1, 2022, 00:00

  • CO7 Evaluating Health Outcomes and Costs Related to In-Hospital Procedures for the Management of Mitral Valve Disease in Spain

    Dec 1, 2022, 00:00

  • EE463 Cost-Effectiveness of Nivolumab as an Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma at High Risk of Recurrence in Switzerland

    Dec 1, 2022, 00:00

  • SA29 Adopting Clinical Trial Best practices of Hybrid Decentralized and Risk Based Quality Management (RBQM), to Help Optimize Prospective Observational (Real-World Evidence) Studies in Compliance, Cost and Time Criteria

    Dec 1, 2022, 00:00

  • HTA205 Time to Reimbursement Decisions for Personalized Medicines in the UK and France

    Dec 1, 2022, 00:00

  • RWD126 Introducing the German MSDS-AOK PLUS Database: Linkage of Administrative Claims Data and a Patient Registry for Advanced RWE Capabilities in Multiple Sclerosis

    Dec 1, 2022, 00:00

  • RWD55 Immunosuppressive (IS) Treatment Patterns Following Kidney Transplant in Fran A Real-World Retrospective Cohort Using the French National Health Data System (SNDS) Claim Databases Oister Study

    Dec 1, 2022, 00:00

  • EE556 Anti-VEGF Cost Calculator in Wet Age-Related Macular Degeneration and Diabetic Macular Edema in Portugal

    Dec 1, 2022, 00:00

  • CO71 EU Joint Clinical Assessment Initiative: Process and Access Strategy Implications

    Dec 1, 2022, 00:00

  • EPH61 Obesity and Glycemic Control Among People With Type 2 Diabetes in Europe: A Retrospective Cohort Analysis

    Dec 1, 2022, 00:00

  • HPR134 Health Policy Analysis of Written Question Motions Submitted to the Presidency and Ministries by the Deputies Between 2018–2022 in Turkiye

    Dec 1, 2022, 00:00

  • HTA90 Use of General Population Utilities in NICE Highly Specialised Technology Appraisals of Treatments With the Potential to Restore Normal Physiology

    Dec 1, 2022, 00:00

  • SA76 Burden of Illness in Patients with Alzheimer’s Disease: A Systematic Review of Incidence, Prevalence, Comorbidities, Disability and Mortality

    Dec 1, 2022, 00:00

  • P35 Real-World Evidence of Incidence, Initial Treatment, and Survival of Female Breast Cancer in Germany

    Dec 1, 2022, 00:00

  • EE338 The Potential Benefit of Respiratory Syncytial Virus (RSV) Vaccination in Older Adults: A Comparison of the United States (US) and United Kingdom (UK)

    Dec 1, 2022, 00:00

  • EE86 Evaluation of Long- Versus Short-Term Use of Patiromer on Healthcare Resource Utilization in the Patiromer Long-Term Use Evaluation (VALUE) Study

    Dec 1, 2022, 00:00

  • EE571 Cost-Effectiveness of Maribavir for Post-Transplant Refractory Cytomegalovirus Infection With or Without Resistan A UK Perspective

    Dec 1, 2022, 00:00

  • HPR7 Out-of-Pocket Health Expenditures of Households With Rare Diseases in Turkiye

    Dec 1, 2022, 00:00

  • PCR236 Estimating Health Utilities for Health States of Patients With Stroke Using the SF-6D

    Dec 1, 2022, 00:00

  • HPR69 Evaluation of Availability, Prices and Affordability of Breast Cancer Medicines in Kwara-Central Senatorial District, Nigeria

    Dec 1, 2022, 00:00

  • MSR142 Combination State Sequence and Process Mining Approach to Develop a Patient-Level Model of Heterogenous Clinical Pathways in Osteoporosis

    Dec 1, 2022, 00:00

  • PCR125 Censoring in the Time Trade-Off Valuation of Worse-Than-Dead EQ-5D-5L Health States: Can a Willingness-to-Accept Question be the Solution?

    Dec 1, 2022, 00:00

  • HTA170 Including Decision-Analytic Benefit-Harm Evaluation in HTA - Different Age Ranges and Screening Intervals in Breast Cancer Screening in Germany

    Dec 1, 2022, 00:00

  • PCR225 Quality of Life (QOL)-Related Mentions for Prevalent Diseases on Social Media Platforms in the US

    Dec 1, 2022, 00:00

  • PCR23 Humanistic Burden and Mental Conditions Among Cancer Patients Before and During the COVID-19 Pandemic in Japan and China

    Dec 1, 2022, 00:00

  • EE48 Can We Afford to Overlook the Cost of Avoidable Complications in Type 2 Diabetes: A Health Economic Analysis to Evaluate What Is the ‘Cost of Not’ Acting in Turkey?

    Dec 1, 2022, 00:00

  • PCR5 Healthcare Resource Use, Productivity and Quality of Life in Patients With Migraine: Results from Overcome (EU) Study

    Dec 1, 2022, 00:00

  • PCR269 People and Families Affected by Gsdia: An Analysis of Narrative Accounts Written by Caregivers and Individuals Living With GSDIa

    Dec 1, 2022, 00:00

  • HPR209 The Unmet Medical Needs Concept – A Structured Analysis of Its Application in Authorisation and Belgian Reimbursement Practices

    Dec 1, 2022, 00:00

  • HTA71 Will the New EU HTA Regulations Increase the Methodological Requirements to Conducting Systematic Literature Reviews of Clinical Evidence?

    Dec 1, 2022, 00:00

  • EPH136 Landscape of Dyslipidemia in China

    Dec 1, 2022, 00:00

  • HTA101 Diagnostic Testing (DTx) Costs: A Hidden Barrier to Accessing Histology-Independent Technologies (HITs)

    Dec 1, 2022, 00:00

  • HTA126 Procedural Issues in Health Technology Assessment (HTA) for Re-Pricing in Japan

    Dec 1, 2022, 00:00

  • EE122 Estimating Hospital Care Costs Associated With Excess Physical Comorbidities in Patients With Mental Health Disorders in Europe

    Dec 1, 2022, 00:00

  • PCR9 Development and Evaluation of Gaucher Disease-Specific Patient Reported Outcome Measurement in Japan

    Dec 1, 2022, 00:00

  • EE103 Evaluating the Need for Automated Technology Solutions in Annual Therapy Cost Calculations in German Early Benefit Assessment Dossiers

    Dec 1, 2022, 00:00

  • PCR84 Myasthenia Gravis Patients Have Lower Eq-5D-5L and HUI3 Utility Values Than a Matched Sample of the General Population: Analysis of Digitally Collected Observational Data from 8 Countries

    Dec 1, 2022, 00:00

  • PCR230 Understanding the Indirect Burden of Patients and Caregivers Impacted by Refractory/Relapsing Multiple Myeloma

    Dec 1, 2022, 00:00

  • EE576 Potential Budget Impact of Negative Pressure Wound Therapy (NPWT) Versus Conventional Wound Treatment in Diabetic Foot Ulcers (DFU), Surgical and Trauma for Selected Countries in Latin America

    Dec 1, 2022, 00:00

  • EPH187 Effects of Non-Pharmaceutical Interventions (NPIS) Aimed at Limiting the Spread of SARS-COV-2

    Dec 1, 2022, 00:00

  • HTA61 Challenges in Selecting Relevant Comparator Therapies in Indications With Low Evidence Using the Example of German Benefit Assessments With the Appropriate Comparator Therapy “Treatment of Physicians Choice"

    Dec 1, 2022, 00:00

  • SA19 A Systematic Literature Review of the Economic Burden of Surfactant Use in the Treatment of Neonates with Respiratory Distress Syndrome

    Dec 1, 2022, 00:00

  • EE465 Cost-Effectiveness of Sotrovimab for the Treatment of Mild-to-Moderate COVID-19 in Patients at High Risk of Disease Progression in Italy

    Dec 1, 2022, 00:00

  • CO45 Real-World Clinical Outcomes of Secukinumab in Thai Patients With Psoriasis: Subgroup Analyses By Adherence Rate and Completeness of Loading Dose

    Dec 1, 2022, 00:00

  • SA15 Propensity Score Matching: Role of Clinical Expertise in a Data-Driven Approach to Model Selection

    Dec 1, 2022, 00:00

  • PCR204 Qualitative Debriefing of the Cystic Fibrosis-Impact Questionnaire (CF-IQ) Among Adolescents With Cystic Fibrosis (CF)

    Dec 1, 2022, 00:00

  • MSR79 Synthesis of Survival Outcomes in Economic Evaluation: Does the Network Meta-Analysis Model Matter?

    Dec 1, 2022, 00:00

  • EE12 Cost of Stroke Management in Turkey

    Dec 1, 2022, 00:00

  • MSR117 Are Classifiers the Future of Artificial Intelligence in Systematic Literature Reviews?

    Dec 1, 2022, 00:00

  • PCR25 Content Validity Assessment of a Newly-Developed Patient-Reported Outcome Measure for Dry Eye Disease (DED), Meibomian Gland Dysfunction (MGD), and Sjogren's Syndrome Dry Eye Disease (SS-DED)

    Dec 1, 2022, 00:00

  • P18 Cancer Drugs Fund Entry and Exit: A Comparison of Key Issues for Decision-Making in NICE Technology Appraisals

    Dec 1, 2022, 00:00

  • MSR112 Evaluating Colombia's Health Insurers Efficiency in Lung Cancer Management: A Data Envelopment Analysis

    Dec 1, 2022, 00:00

  • SA51 Different Ways to Present a DCE to Respondents: A Scoping Review

    Dec 1, 2022, 00:00

  • RWD5 Using Linked Databases to Explore Resource Use and Real-World Outcomes in a Rare Disease: Pompe Disease in England

    Dec 1, 2022, 00:00

  • CO167 The Incremental Benefit Provided by Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL) When Compared to Real-World Clinical Practice (RWCP)

    Dec 1, 2022, 00:00

  • MSR114 Current Scenario of ‘Scenario Analysis’ in Health Economic Modelling in Oncology: A Review of NICE Appraisals

    Dec 1, 2022, 00:00

  • EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study

    Dec 1, 2022, 00:00

  • HTA258 Health Technology Assessments of Single-Arm Clinical Trials in Germany and France

    Dec 1, 2022, 00:00

  • MSR15 Using Advanced Parametric Survival Models for HTA Submissions in the Face of Short-Term Patient Follow-Up

    Dec 1, 2022, 00:00

  • HTA114 Review of Health Technology Assessment (HTA) and Recommendations for the Introduction of Higher-Valency Pneumococcal Conjugated Vaccine (PCV) in 4 European Countries, The United-Kingdom (UK), and The United-States (US)

    Dec 1, 2022, 00:00

  • P12 Addressing the Distributional Consequences of Spillovers in Health Economic Evaluation: A Prioritarian Approach

    Dec 1, 2022, 00:00

  • HPR97 National Reimbursement Drug List Negotiation in China: Analysis of the Key Trends and Factors Influencing the Value Appraisal and Price Determination

    Dec 1, 2022, 00:00

  • HTA54 Incorporating Value of Health System Impact in Economic Evaluations of Therapies of Chronic Diseases

    Dec 1, 2022, 00:00

  • HPR67 Identifying the Key Challenges in the Reimbursement of Next Generation Sequencing and Future Policy Changes in Europe Using a Web-Based Portal to Engage Payers

    Dec 1, 2022, 00:00

  • MSR72 Collaborative, Multisectoral, and Multidisciplinary Approach to Enhance FDA One Health Initiative Communication Strategies

    Dec 1, 2022, 00:00

  • EE393 Cost Effectiveness Analysis of DTG/3TC Versus EVG/c/TAF/FTC and BIC/TAF/FTC for HIV-1 Infection Management in Treatment-Naïve Patients in China

    Dec 1, 2022, 00:00

  • Frameworks and Methods for the Design of Stated Preference

    Dec 1, 2022, 00:00

  • EE454 A Distributional Cost-Effectiveness Analysis of Screening Strategies for Ovarian Cancer

    Dec 1, 2022, 00:00

  • PCR157 The Impact of Single Pill Combination Versus Free Dose Equivalent on Outcomes in Patients With Hypertension and/or Dyslipidaemia: A Systematic Review

    Dec 1, 2022, 00:00

  • HTA47 Definition of a System of Factors to Improve the Quality of Decision-Making Process in Health Technology Assessment

    Dec 1, 2022, 00:00

  • HPR188 Characterizing the Relevance of IRP for Medical Devices: A Cross-Country Comparison

    Dec 1, 2022, 00:00

  • HTA207 Managed Entry Agreements in the Context of Health Technology Assessment Recommendations in Ukraine: Analysis on the Stage of Development

    Dec 1, 2022, 00:00

  • PCR94 Difference in Health-Related Quality of Life Among People With and Without Disabilities

    Dec 1, 2022, 00:00

  • CO60 Mortality Impact Following the EU Approval of Numerous Novel Non-Small Cell Lung Cancer (NSCLC) Therapies Between 2010-2020

    Dec 1, 2022, 00:00

  • RWD97 Cost of COPD Hospitalizations in the Brazilian Public Health

    Dec 1, 2022, 00:00

  • EE615 Economic Burden and Quality of Life in Prurigo Nodularis: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE88 Impact of Rational Use of Palivizumab in the Treatment of RSV in a Private Health Insurance Company in Brazil

    Dec 1, 2022, 00:00

  • HPR34 Emerging Role of Patient Reported Outcomes in Drug Approval in Europe

    Dec 1, 2022, 00:00

  • EE577 Cost-Consequence Analysis of EPTFE Vascular Grafts With Heparin End Point Covalent Bond Compared to Standard EPTFE Vascular Grafts in Below-Knee Surgical Bypass for Critical Limb Ischaemia Pad Patients in Portugal

    Dec 1, 2022, 00:00

  • EE261 Cost and Resource Studies in Endometriosis: An Evidence Map

    Dec 1, 2022, 00:00

  • P6 EMA/EUnetHTA Qualification of the IMI PREFER Patient Preference Framework and Points to Consider for Method Selection: Key Experiences, Outcomes, Value and Implications

    Dec 1, 2022, 00:00

  • EPH44 Prevalence and Risk Profile of Emerging Multidrug Resistance in Klebsiella Pneumoniae/ Enterobacteriaceae: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19

    Dec 1, 2022, 00:00

  • EE572 Cost-Effectiveness of AZD7442 (Tixagevimab and Cilgavimab) for Pre-exposure Prophylaxis Against COVID-19 in the Immunocompromised Population

    Dec 1, 2022, 00:00

  • EE391 Impact of the COVID-19 Pandemic on the Healthcare Resource Use of People With Newly Diagnosed Mood/Affective Disorder

    Dec 1, 2022, 00:00

  • PCR103 Patients and Neurologists’ Preferences for Remote Patient Monitoring and Artificial Intelligence to Improve Parkinson's Disease Management

    Dec 1, 2022, 00:00

  • EE317 An Unresolved Paradox: The Additional Challenge of Demonstrating Cost-Effectiveness for Innovative Treatments Addressing Diseases With High Unmet Need

    Dec 1, 2022, 00:00

  • PCR62 The Australian Paediatric Multi-Instrument Comparison (P-MIC) Study: Data Quality, Feasibility, Acceptability, and Construct Validity of the EQ-5D-Y-3L, EQ-5D-Y5L, CHU9D, PedsQL, HUI, PROMIS-25 and AQoL-6D

    Dec 1, 2022, 00:00

  • EE419 Economic Evaluation of Extracorporeal Membrane Oxygenation (ECMO) vs Invasive Ventilation for COVID-19 Patients with Severe Acute Respiratory Distress Syndrome (ARDS)

    Dec 1, 2022, 00:00

  • CO95 The Relationship Between Asthma Control Questionnaire Scores and Exacerbation Risk, Resource Utilization, and Utility Values: An Analysis From the Captain Trial

    Dec 1, 2022, 00:00

  • PCR29 A Systematic Literature Review of Utility Estimates for Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

    Dec 1, 2022, 00:00

  • PCR202 The Nature of Quality Appraisal in Systematic Literature Reviews of Health State Utility Values (HSUVS): A Rapid Evidence Review

    Dec 1, 2022, 00:00

  • SA43 Rapid Evidence Publication in the COVID-19 Era: Impact on Study Quality and Study Identification

    Dec 1, 2022, 00:00

  • EE409 Cost Effectiveness of Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

    Dec 1, 2022, 00:00

  • CO119 Systematic Review and Meta-Analysis of Mucosal Healing Outcomes With Biologics in Treatment of Ulcerative Colitis and Crohn's Disease

    Dec 1, 2022, 00:00

  • EE520 Cost of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) in Spain: A Delphi Approach

    Dec 1, 2022, 00:00

  • HPR26 Anti-PD(L)1: Does the Cost of Treatment Have an Impact on the Therapeutic Decision-Making?

    Dec 1, 2022, 00:00

  • EE71 Cost-Effectiveness of Screening for Hydroxychloroquine Retinopathy

    Dec 1, 2022, 00:00

  • RWD167 The Impact of Administration Modality on Quality of Life for Respiratory Diseases in Japan Based on Patient-Reported Outcomes

    Dec 1, 2022, 00:00

  • PCR51 Reassessing the Acceptability of Risk of Death Associated With Gene Therapy for Duchenne Muscular Dystrophy: A Qualitative Study to Inform Updating a Quantitative Instrument

    Dec 1, 2022, 00:00

  • P66 Understanding of Post-COVID Conditions (PCC) and Related Burden of Illness

    Dec 1, 2022, 00:00

  • HPR205 Future-Proofing European Regulatory and Market Access Practices Based on Learnings From the COVID-19 Pandemic – Stakeholder Perspectives

    Dec 1, 2022, 00:00

  • HTA34 Quo Vadis Benefit Assessment for Orphan Drugs in Germany: The End of the Exception?

    Dec 1, 2022, 00:00

  • EE625 Economic and Clinical Burden of Worsening Heart Failure Patients With Reduced Ejection Fraction: French National Healthcare Database Analysis (SNDS)

    Dec 1, 2022, 00:00

  • EE489 The Cost of Treatment with Dupilumab in Severe Asthma Patients With Coexisting Other Type 2 Inflammatory Diseases

    Dec 1, 2022, 00:00

  • RWD78 First Real-World Evidence Study of Patients With Hemophilia in Algeria

    Dec 1, 2022, 00:00

  • EE402 Social and Economic Burden of Breast Cancer in Russia

    Dec 1, 2022, 00:00

  • RWD69 Healthcare Resource Use by European Patients Enrolled in RA-BE-REAL: 12 Month Data From a Multinational, Prospective, Observational Study of Patients With Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • EE596 Comparative Evaluation of the Health Utilities Index Mark 3 and the Short Form-6D: Evidence From an Individual Participant Data Meta-Analysis of Very Preterm and Very Low Birthweight Adults

    Dec 1, 2022, 00:00

  • HPR28 Last Resort for Reimbursement of New Drugs in Germany: When the Arbitration Office Must Decide

    Dec 1, 2022, 00:00

  • EE420 Valuation of Lost Productivity for Individuals Diagnosed With Osteogenesis Imperfecta: Follow-up Findings From the Rudy Cohort Study in the UK

    Dec 1, 2022, 00:00

  • EPH105 Changes in the Prevalence of Gestational Diabetes Mellitus and Associated Syndromes of Infants — The Case of Hungary

    Dec 1, 2022, 00:00

  • MSR42 Adoption of Artificial Intelligence in Systematic Reviews

    Dec 1, 2022, 00:00

  • HTA96 Health Economic Modelling for HTA Assessment: A Comparison of Economic Protocols Submitted to Three HTA Bodies (HAS, NICE, CADTH)

    Dec 1, 2022, 00:00

  • PCR265 Preferences and Needs of Heart Failure Patients Regarding Their Treatment and Care

    Dec 1, 2022, 00:00

  • HSD102 Physicians’ Experience and Perceptions of Tetrabenazine for the Treatment of Huntington Disease-Related Chorea

    Dec 1, 2022, 00:00

  • HTA158 A Comparison of HTA Economic Results in Ireland: The Applicant and Assessor Perspectives

    Dec 1, 2022, 00:00

  • HTA53 Will NICE’S New Severity Weighting Criteria Be Capable of Identifying Severe Conditions?

    Dec 1, 2022, 00:00

  • MSR7 Multiplicative With Linear Transformation (MLT): An Improvement on the Multiplicative Method for Age and Sex Adjustment of Utilities?

    Dec 1, 2022, 00:00

  • CO111 Evaluating Mediator Factors Affecting Breast Cancer Screening in American Women: An Application of the Andersen's Behavioral Model to 2011 to 2015 MEPS Panel Data

    Dec 1, 2022, 00:00

  • PCR197 Psychometric Evaluation of a New Electronic Pediatric Asthma Symptom Diary

    Dec 1, 2022, 00:00

  • P47 Understanding Evidence Requirements for Diagnostic Devices for Reimbursement and Market Access: Insights and Lessons From Review of NICE Diagnostics Assessment Reports (2011-2022)

    Dec 1, 2022, 00:00

  • RWD54 Healthcare Resource Use and Associated Costs of Congenital Thrombotic Thrombocytopenic Purpura in France

    Dec 1, 2022, 00:00

  • EE415 Cost Utility Analysis of Ocrelizumab Versus Fingolimod in Relapsing Remitting Multiple Sclerosis Patients in Egypt from Payor Perspective

    Dec 1, 2022, 00:00

  • HSD10 Medical Cannabis Legalization and Opioid- and Pain- Related Outcomes Among U.S. Patients Newly Diagnosed With Cancer and Receiving Anti-Cancer Treatment

    Dec 1, 2022, 00:00

  • HSD108 Physician Perceptions on the Treatment and Health-Related Quality of Life Burden of Endogenous Cushing's Syndrome

    Dec 1, 2022, 00:00

  • HTA193 Criteria for Value Assessment of Medication Adherence-Enhancing Interventions: Preliminary Results of a Systematic Review

    Dec 1, 2022, 00:00

  • EE666 Cost-Analysis of the Introduction of a Second Generation Biomarker Breast Cancer Prognostic Test for the Management of Early Breast Cancer in Greece

    Dec 1, 2022, 00:00

  • EPH26 Three-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Incidence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics

    Dec 1, 2022, 00:00

  • RWD37 Healthcare Resource Use and Associated Costs of Dengue Fever Requiring Hospitalization: A French National Real-World Study

    Dec 1, 2022, 00:00

  • Analytic Methods for the Effectiveness of Immunotherapies in Oncology

    Dec 1, 2022, 00:00

  • EE249 Incorporating Litigation Costs in Economic Evaluation

    Dec 1, 2022, 00:00

  • HTA68 Digital Health – Where Do We Stand From a Market Access Perspective in the EU-4 and the UK?

    Dec 1, 2022, 00:00

  • MT32 Rise of the Machines – Analysis of Robotic-Assisted Surgery From 2005 to 2020 Based on German Hospital Data

    Dec 1, 2022, 00:00

  • PCR132 Is Walking as Important as Communicating After Stroke? Preference Weighting of ICF's Core Elements

    Dec 1, 2022, 00:00

  • P64 Health-Related Quality of Life in HER2-Positive Early Breast Cancer Woman Using Trastuzumab: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • PCR267 Evaluating Patient-Reported Experience Along the Inflammatory Bowel Disease Patient Journey in Portugal

    Dec 1, 2022, 00:00

  • EE220 Healthcare Costs of Osteoporotic Fractures in Nigeria

    Dec 1, 2022, 00:00

  • P20 Health Technology Assessment Based on Real-World Data: Estimating Lifetime Survival and Costs With Empirical Examples from Taiwan

    Dec 1, 2022, 00:00

  • PCR145 Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy (SMA) in Italy

    Dec 1, 2022, 00:00

  • MT7 Artificial Intelligence Applied to Motor Activities: A Rapid Review of the Literature

    Dec 1, 2022, 00:00

  • EPH180 Acute Coronary Heart Syndrom (ACS): Hospitalizations in Germany Before and During COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • EE510 A Global Analysis of the Value of Precision Medicine in Oncology – The Case of Non-Small Cell Lung Cancer

    Dec 1, 2022, 00:00

  • RWD138 Age-Distribution in ICD-10 Codes Used to Document Hospitalised RSV Burden in Infants in England

    Dec 1, 2022, 00:00

  • HPR11 Could DiGA be a Role-Model for a New Digital Health Process in the UK?

    Dec 1, 2022, 00:00

  • HPR86 Sustainability of Healthcare Systems in the Wake of COVID-19: The UK VPAS Case Study

    Dec 1, 2022, 00:00

  • EE619 The Economic Impact of Empagliflozin in Adult Patients With Chronic Heart Failure in Spain

    Dec 1, 2022, 00:00

  • SA53 Misdiagnosis and Disease-Exacerbating Medication Use in Patients With Neuromyelitis Optica Spectrum Disorder in the United States: A Retrospective Claims Analysis

    Dec 1, 2022, 00:00

  • Natural Language Processing for Automated Classification of Qualitative Data From Interviews of Patients With Cancer

    Dec 1, 2022, 00:00

  • EE455 Assessing the Consequences of Suboptimal Infant Vaccination Rates on Pertussis Costs in Brazil: A Prospective Modeling Analysis

    Dec 1, 2022, 00:00

  • EE383 The Economic Burden of COVID-19 Prevention and Cases Management in Egypt from Governmental Perspective

    Dec 1, 2022, 00:00

  • HTA269 What Are the Emerging State-of-the-Art HTA Methods That Are Relevant to Harmonization of HTA Across Jurisdictions?

    Dec 1, 2022, 00:00

  • HPR96 Trends in European Pharmaceutical Tender Requirements and Opportunities for Differentiation for Biosimilars

    Dec 1, 2022, 00:00

  • HTA233 Analysis: First Year of the New Early Access Authorization in France

    Dec 1, 2022, 00:00

  • HPR106 The Challenges of Outcomes-Based Reimbursement for Advanced Therapy Medicinal Products in Europe

    Dec 1, 2022, 00:00

  • MSR84 Training Models for Machine-Enabled Systematic Literature Reviews: Do Large Datasets Always Give Better Results?

    Dec 1, 2022, 00:00

  • HPR6 Analysis of Patient Access to Personalized Oncology Medicines in Turkiye

    Dec 1, 2022, 00:00

  • CO115 Impact of Patient Blood Management (PBM) on the Reduction of Transfusion Requirements in Patients Undergoing Major Planned Orthopedic Surgery in Italy

    Dec 1, 2022, 00:00

  • MSR29 Benchmarking Current Practices in Data Visualisation in HEOR, Identifying Gaps and Suggesting Improvements

    Dec 1, 2022, 00:00

  • HTA106 HTA and Reimbursement Timelines in the Republic of Ireland

    Dec 1, 2022, 00:00

  • EE93 Economic Consequences of the Implementation of HPV Screening in Bulgaria

    Dec 1, 2022, 00:00

  • PCR286 Literature Review of Patient-Reported Outcome Measures in Multiple Myeloma: Trends and Considerations for Future Clinical Trials

    Dec 1, 2022, 00:00

  • CO29 The Very Long-Term Durability of TEVAR for Traumatic Aortic Transection Determined by Real-World Evidence

    Dec 1, 2022, 00:00

  • EPH41 Evaluating Population Health Priorities for Community Health Workers

    Dec 1, 2022, 00:00

  • EE641 Economic and Health-Related Quality of Life Consequences of Imaging and Surveillance Schedule in Seminoma Testis

    Dec 1, 2022, 00:00

  • RWD120 Understanding Treatment Patterns, Disruptions and Potential Limitations of Tyrosine Kinase Inhibitors in ROS1+ Non-Small Cell Lung Cancer Patients in a Retrospective Review of United States Medical Transcription Records

    Dec 1, 2022, 00:00

  • MSR21 Exploration of the Impact of the Treatment Mechanism of Action on the Surrogate Relationship Between Progression Free Survival and Overall Survival in Metastatic Colorectal Cancer

    Dec 1, 2022, 00:00

  • CO80 Surrogate Endpoints for Overall Survival in Cutaneous Squamous Cell Carcinoma: A Meta-Regression of Clinical Trials

    Dec 1, 2022, 00:00

  • SA3 Effect of Mortality on Cost-Effectiveness Modeling of Disease-Modifying Treatment for Alzheimer's Disease

    Dec 1, 2022, 00:00

  • OP15 Assessment of the Clawback and Rebate Policies on the Efficiency of Greek Public Hospitals Between 2009-2019

    Dec 1, 2022, 00:00

  • EE170 Cost-Effectiveness of a Digital Diabetes Prevention Program (DDPP) in Prediabetic Patients

    Dec 1, 2022, 00:00

  • MT21 Living With Orthopaedic Implants: Results of an Online Cross-Sectional Study in Hungary

    Dec 1, 2022, 00:00

  • EE54 Haemophilia Lifetime Cost Comparison for Austria: Annual Drug Costs in Comparison With Projected Gene Therapy Costs

    Dec 1, 2022, 00:00

  • HPR121 By Any Genes Necessary: An Eventful 12 Months in the Gene Therapy Pipeline

    Dec 1, 2022, 00:00

  • EE521 Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Bone Conduction Implants (BCI): A Case Study of a Longitudinal Economic Analysis and a Markov Model-Based Simulation.

    Dec 1, 2022, 00:00

  • HTA37 The NICE Disease Severity Modifier: A Retrospective Analysis on Its Potential Impact on Previous Reimbursement Decisions in England

    Dec 1, 2022, 00:00

  • SA74 'How Easily Could You Obtain Proof of Diagnosis for Your Medical Condition?' Feedback From Individuals With Chronic Medical Conditions on a Digital Diagnosis Validation Feature

    Dec 1, 2022, 00:00

  • HTA122 Health-Related Quality of Life in the German Early Benefit Assessment

    Dec 1, 2022, 00:00

  • EPH89 Epidemiology of Myxoid Round Cell Liposarcoma (MRCLS) in the European Union (EU27) – An Extrapolation From the United States (US) Surveillance, Epidemiology, and End Results (SEER) Research Database

    Dec 1, 2022, 00:00

  • EPH183 Effect of Renin-Angiotensin System Inhibitors on Alzheimer’s Disease: A Population-Based Cohort Study

    Dec 1, 2022, 00:00

  • P54 Antimicrobial Resistance Associated With Worse Outcomes in Hospitalized Adults With Pneumococcal Disease

    Dec 1, 2022, 00:00

  • HPR53 Changes to Early Access Scheme in Fran Early Learnings for Orphan Drugs

    Dec 1, 2022, 00:00

  • HPR48 Reimbursement Policies Regarding Rare Diseases in Central and Eastern European Countries

    Dec 1, 2022, 00:00

  • EE350 Selective Internal Radiation Therapy Using Y-90 Resin Microspheres vs Conventional Transarterial Chemoembolization in Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma: A Budget Impact Analysis in England

    Dec 1, 2022, 00:00

  • CO143 Project Ideate: Creating a Novel Linked Real World Data Environment in Wales for Use in an Experimental, Retrospective Outcome-Based Agreement of a Breast Cancer Treatment

    Dec 1, 2022, 00:00

  • HTA32 Does a Major Added Benefit From the G-Ba Correspond to Positive Outcomes Across Major Markets? An Analysis Based on the Prismaccess Database

    Dec 1, 2022, 00:00

  • PCR185 The Role of Patients’ Advocacy Groups in the Italian Health Care Ecosystem: Present and Future Perspectives

    Dec 1, 2022, 00:00

  • MSR38 Can Logistic Regression (LOR) Better Predict the Significance of the Overall Survival (OS) from Surrogate Endpoints (SES) for Randomized Controlled Trials (RCTS) in Oncology? Insights From a Cross-Tumor Case Study

    Dec 1, 2022, 00:00

  • HTA140 Current Changes in Europe Impacting Orphan Drugs Access: A Focus on the Latest Reforms in the EU4 and England

    Dec 1, 2022, 00:00

  • OP8 Developing Sustainable Partnerships Between Pharmaceutical Industry and Public and Non-Profit Organisations: Report of a Roundtable Discussion

    Dec 1, 2022, 00:00

  • PCR233 The Case Studies of an Integrative Approach in Primary Healthcare of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Post-COVID-19 Patients

    Dec 1, 2022, 00:00

  • EE683 Evaluation of the Healthcare Resource Use of Haemodialysis Patients With and Without Pruritus in the UK

    Dec 1, 2022, 00:00

  • EPH8 Factors Associated With Oral Anticoagulant Switching in Patients With Atrial Fibrillation

    Dec 1, 2022, 00:00

  • EE675 Cost-Utility Analysis of Metabolic Surgery Compared With Best Medical Care for the Treatment of Comorbid Type 2 Diabetes and Obesity

    Dec 1, 2022, 00:00

  • EE671 Budgetary Impact and Health Outcomes of Implementing New Treatment Guidelines for Heart Failure in Norway

    Dec 1, 2022, 00:00

  • RWD141 Exploration of Melanoma Patient-Generated Real-World Data Using an Ai-Based Social Listening Approach

    Dec 1, 2022, 00:00

  • EE67 Cost Per Responder and Number Needed to Treat of iGlarlixi vs Premix BIAsp 30 in Algerian Setting

    Dec 1, 2022, 00:00

  • MT1 FLT3 Inhibitors for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia: Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • EPH151 Clinical and Economic Benefits of Prompt Initiation of Single-Inhaler Triple Therapy in COPD Patients in England Following an Exacerbation

    Dec 1, 2022, 00:00

  • HTA202 Learnings From First TC Opinions of Drugs Evaluated for EAP Under New Process

    Dec 1, 2022, 00:00

  • Paying for Kidneys: Reflections on Welfare Economics, Political Economy, and Market Design

    Dec 1, 2022, 00:00

  • EE6 Economic Burden of Severe Asthma in Adults and Children Treated With Omalizumab From 2012 to 2019

    Dec 1, 2022, 00:00

  • EE94 Cost-Effectiveness Analysis of Vaccinating Against Herpes Zoster With Adjuvanted Recombinant Zoster Vaccine in Switzerland

    Dec 1, 2022, 00:00

  • PCR190 Health-Related Quality of Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis

    Dec 1, 2022, 00:00

  • HPR197 Designing a Performance-Based Risk Sharing Arrangement for Aducanumab

    Dec 1, 2022, 00:00

  • P10 Modelling Spillover Effects on Informal Carers: The 'Carer QALY Trap'

    Dec 1, 2022, 00:00

  • MSR26 The Use of Disease-Specific Health-Related Quality of Life (HRQOL)/ Patient Reported Outcomes (PROS) Scales in Rare Inflammatory Conditions (RICS)

    Dec 1, 2022, 00:00

  • HPR18 Pharmacoeconomic Evaluation of Orphan Drugs in the United Kingdom, France, Italy, Turkey and Exploration of the Evaluation Process of Orphan Drugs in Algeria

    Dec 1, 2022, 00:00

  • CO8 Ponatinib vs Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia: A Matching Adjusted Indirect Comparison

    Dec 1, 2022, 00:00

  • EE216 Expenditure on Medicines for the Treatment of Multiple Myeloma in Catalonia for 2021

    Dec 1, 2022, 00:00

  • EE189 Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification

    Dec 1, 2022, 00:00

  • EPH92 Dysphagia Prevalence in Brazil, UK, China, and Indonesia and Dysphagic Patient Preferences

    Dec 1, 2022, 00:00

  • EE633 A Targeted Literature Review of the Modelling Approaches and Challenges in Early-Stage Oncology Treatment Sequence Models

    Dec 1, 2022, 00:00

  • HTA132 Suitability of Value-Based Price Forecasting in a Crowded Landscape: A Case Study in Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • HPR161 A Long-Term Forecast of the Economic Impact of Gene Therapies in France

    Dec 1, 2022, 00:00

  • EE599 Cost-Effectiveness Analysis of Trastuzumab Emtansine for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in Greece

    Dec 1, 2022, 00:00

  • EE29 Burden of Disease and Cost of Illness of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Bulgaria

    Dec 1, 2022, 00:00

  • EE106 Cost-Effectiveness Analysis of Bimekizumab in Patients With Moderate-to-Severe Plaque Psoriasis in Greece

    Dec 1, 2022, 00:00

  • HSD61 Trends in Discontinuation of Lipid-Lowering and Antihypertensive Therapies: A Real-World Data Analysis in Italy

    Dec 1, 2022, 00:00

  • EE503 Cost Implications of Hospice Care for Cancer Patients in Illinois Hospitals

    Dec 1, 2022, 00:00

  • MT44 Extent of Use of Artificial Intelligence and Machine Learning Protocols in Cancer Diagnosis: A Scoping Review

    Dec 1, 2022, 00:00

  • EE78 Mapping the Value for Money of Precision Medicine: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • PCR292 Health State Utility Values (HSUVs) and Health-Related Quality of Life (HRQoL) in People Living With HIV/AIDS (PLWH): A Systematic Literature Review (SLR)

    Dec 1, 2022, 00:00

  • SA62 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in Asthma in England: A Population-Based Study

    Dec 1, 2022, 00:00

  • RWD157 Challenges and Opportunities of Using Electronic Health Records in Multi-Country Studies

    Dec 1, 2022, 00:00

  • CO55 Radiographic Progression-Free Survival (RPFS) as a Surrogate Endpoint for Overall Survival (OS) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (MCRPC): A Correlation Meta-Analysis

    Dec 1, 2022, 00:00

  • EPH54 Prevalence and Association of Sociodemographic Determinants With the Risk of Developing Type 2 Diabetes in Saudi Arabia: A Web-Based Cross-Sectional Survey Study

    Dec 1, 2022, 00:00

  • Copyright/Subscription

    Dec 1, 2022, 00:00

  • HTA151 The NICE Cost Comparison Pathway - How Much Evidence Is Required to Meet the Criteria?

    Dec 1, 2022, 00:00

  • MSR118 Machine Learning Approaches Towards Identification of Phenotypes in Various Diseases Using Electronic Health Records

    Dec 1, 2022, 00:00

  • EPH157 Physical Activity Level in Association with Mental Health Before and During the Restrictions of the First Three Waves of COVID-19 Pandemic Among Hungarian Adults

    Dec 1, 2022, 00:00

  • MT28 Effects of Mobile Health-Based Personalized Disease Management Program Intervened by Health Professionals Through a Mobile App and Telephone Interviews in Reducing Medical Costs

    Dec 1, 2022, 00:00

  • MSR14 Developing an Abbreviated WHOQOL-BREF for Patients With Major Chronic Diseases Using the IRT Model

    Dec 1, 2022, 00:00

  • RWD57 Epidemiological Study of the Burden of COVID-19 on Depression in Men (DIM) in Pre- and During COVID-19 Pandemic Using Real-World Data

    Dec 1, 2022, 00:00

  • RWD130 The Effect of the COVID-19 Pandemic in the Prevalence of Diabetes Mellitus Type 1 and 2 in Children and Young Adults in Gree Real World Data from Greece

    Dec 1, 2022, 00:00

  • EE364 Reduced Healthcare Resource Use in Patients With Chronic Insomnia After Treatment With a Digital Therapeutic With 2-Year Follow-Up

    Dec 1, 2022, 00:00

  • EE18 Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders

    Dec 1, 2022, 00:00

  • HTA208 Health Technology Assessment Impact on the Health Care System in Challenging Times in Ukraine

    Dec 1, 2022, 00:00

  • EE52 Cost-Minimisation Analysis of Ravulizumab Compared With Eculizumab in Patients With Atypical Hemolytic Uremic Syndrome (AHUS) in the Netherlands

    Dec 1, 2022, 00:00

  • PCR74 Development of Conceptual Frameworks and Patient-Reported Outcome Measures in Glycogen Storage Disease Type Ia (GSDIa)

    Dec 1, 2022, 00:00

  • CO11 Comparison of Relapse Rates in Ulcerative Colitis Patients With Mayo Endoscopic Score of 0 or 1: Systematic Literature Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • EE277 Cost-Effectiveness of Lanreotide ATG Verse Octreotide for the Treatment of Acromegaly in China

    Dec 1, 2022, 00:00

  • EE191 A Budget Impact Analysis of Selective Internal Radiation Therapy Using Y-90 Resin Microspheres Versus Atezolizumab-Bevacizumab as First-Line Therapy in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma in England

    Dec 1, 2022, 00:00

  • HPR193 Investigating the Correlation Between UK-Based Clinical Research and NICE Decision Making

    Dec 1, 2022, 00:00

  • EE200 A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs (NNIADS): Trends in Decision-Analytical Models (DAM) for Modelling of Type 2 Diabetes Mellitus (T2DM)

    Dec 1, 2022, 00:00

  • PCR96 Effects of Intravenous Iron Infusion Frequency, Duration, and Safety on Quality of Life: Results of a Time Trade-Off Study in Patients With Iron Deficiency Anemia in China

    Dec 1, 2022, 00:00

  • EPH192 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Generalized Pustular Psoriasis Patients: A Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics

    Dec 1, 2022, 00:00

  • EPH162 Pilot Study to Assess the Prevalence of Advanced Gastrointestinal Stromal Tumor Identified Using German Claims Data

    Dec 1, 2022, 00:00

  • EE280 Economic Burden of Hyperkalemia in Turkey

    Dec 1, 2022, 00:00

  • HPR115 When to Expect Economic Appraisal in France? A Study Based on 2021 Appraisal

    Dec 1, 2022, 00:00

  • HPR151 Has Project Orbis Facilitated Faster Access to Oncology Therapies in Great Britain Following 'Brexit'?

    Dec 1, 2022, 00:00

  • EE403 Health and Economic Impact of a Novel 3-Antigen Vaccine for the Prevention of Hepatitis B in Adults in Germany: A Cost-Effectiveness Analysis

    Dec 1, 2022, 00:00

  • CO131 Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Patients in Finland (FINPAH) – A Descriptive Retrospective Real World Cohort Study Between 2008 and 2020

    Dec 1, 2022, 00:00
  • «
  • 31
  • 32
  • 33 (current)
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • »